JP2023527049A - 養子細胞療法に有用なポリペプチド - Google Patents

養子細胞療法に有用なポリペプチド Download PDF

Info

Publication number
JP2023527049A
JP2023527049A JP2022572753A JP2022572753A JP2023527049A JP 2023527049 A JP2023527049 A JP 2023527049A JP 2022572753 A JP2022572753 A JP 2022572753A JP 2022572753 A JP2022572753 A JP 2022572753A JP 2023527049 A JP2023527049 A JP 2023527049A
Authority
JP
Japan
Prior art keywords
seq
sequence
polypeptide
cells
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527049A5 (cg-RX-API-DMAC7.html
Inventor
マルティネス‐ローデラ、マーク
ボルンシャイン、ジーモン
Original Assignee
クウェル セラピューティックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クウェル セラピューティックス リミテッド filed Critical クウェル セラピューティックス リミテッド
Publication of JP2023527049A publication Critical patent/JP2023527049A/ja
Publication of JP2023527049A5 publication Critical patent/JP2023527049A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022572753A 2020-05-26 2021-05-26 養子細胞療法に有用なポリペプチド Pending JP2023527049A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2007842.4 2020-05-26
GBGB2007842.4A GB202007842D0 (en) 2020-05-26 2020-05-26 Polypeptide useful in adoptive cell therapy
PCT/EP2021/064053 WO2021239812A1 (en) 2020-05-26 2021-05-26 Polypeptide useful in adoptive cell therapy

Publications (2)

Publication Number Publication Date
JP2023527049A true JP2023527049A (ja) 2023-06-26
JP2023527049A5 JP2023527049A5 (cg-RX-API-DMAC7.html) 2024-05-29

Family

ID=71406309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572753A Pending JP2023527049A (ja) 2020-05-26 2021-05-26 養子細胞療法に有用なポリペプチド

Country Status (9)

Country Link
US (1) US20230183311A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157318A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023527049A (cg-RX-API-DMAC7.html)
CN (1) CN115955977A (cg-RX-API-DMAC7.html)
AU (1) AU2021279184A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179441A1 (cg-RX-API-DMAC7.html)
GB (2) GB202007842D0 (cg-RX-API-DMAC7.html)
TW (1) TW202210503A (cg-RX-API-DMAC7.html)
WO (1) WO2021239812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227756B2 (en) 2018-04-18 2025-02-18 Ucl Business Ltd Engineered regulatory T cell
TW202321286A (zh) 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
WO2023047100A1 (en) 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-trem2 chimeric antigen receptor
GB202117298D0 (en) 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
US20250017967A1 (en) 2021-12-17 2025-01-16 Quell Therapeutics Limited Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells
EP4453022A1 (en) 2021-12-22 2024-10-30 Quell Therapeutics Limited Constitutive cytokine receptors
EP4496883A1 (en) 2022-03-22 2025-01-29 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
EP4519294A1 (en) * 2022-05-04 2025-03-12 Earli Inc. Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells
GB202217541D0 (en) 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
JP2026507781A (ja) 2023-01-23 2026-03-06 メディツィニシェ ホゥーシュル ハノーファー キメラ抗原受容体
CN120787258A (zh) 2023-02-07 2025-10-14 圭尔医疗有限公司 Treg细胞培养方法
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194649A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t cells and uses thereof
WO2024194642A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t regulatory cell
EP4442322A1 (en) 2023-04-06 2024-10-09 Medizinische Hochschule Hannover Liver-specific car for use against immunologic rejection
CN121586727A (zh) 2023-06-21 2026-02-27 圭尔医疗有限公司 组成型细胞因子受体
EP4766382A1 (en) 2023-08-24 2026-07-01 Medizinische Hochschule Hannover BECAUSE FOR THE TREATMENT OF MS OR MA
EP4512415A1 (en) 2023-08-24 2025-02-26 Medizinische Hochschule Hannover Chimeric antigen receptor for treatment of multiple sclerosis or alzheimer's disease
US20260176598A1 (en) 2024-07-04 2026-06-25 Quell Therapeutics Limited Expression construct
EP4678187A1 (en) 2024-07-11 2026-01-14 Medizinische Hochschule Hannover Compound for use in the treatment of inflammatory bowel disease
WO2026027876A1 (en) 2024-07-29 2026-02-05 Quell Therapeutics Limited Chimeric antigen receptor
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518479A (ja) * 2012-04-13 2015-07-02 ユーシーエル ビジネス ピーエルシー 養子細胞療法に有用なポリペプチド
JP2018504458A (ja) * 2015-01-26 2018-02-15 セレクティスCellectis 操作された免疫細胞の選別/枯渇のための、mAbが推進するキメラ抗原受容体系
JP2018512153A (ja) * 2015-04-13 2018-05-17 ファイザー・インク B細胞成熟抗原を標的にするキメラ抗原受容体
JP2020512019A (ja) * 2017-03-31 2020-04-23 セレクティス ソシエテ アノニム ユニバーサル抗cd22キメラ抗原受容体操作免疫細胞

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2528595A1 (en) 2003-06-13 2005-01-06 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
KR20080039844A (ko) 2005-05-24 2008-05-07 아베스타 겐그레인 테크놀로지스 피브이티 리미티드 B―세포 림프종 치료를 위한 cd20에 대한 모노클로날항체의 제조 방법
GB201415344D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Protein
US10604586B2 (en) 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
MX2020010808A (es) * 2018-04-13 2021-03-02 Sangamo Therapeutics France Receptor de antigeno quimerico especifico para el receptor de interleucina-23.
CN112996819B (zh) * 2018-08-16 2025-11-04 纪念斯隆-凯特琳癌症中心 细胞分选系统及使用方法
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518479A (ja) * 2012-04-13 2015-07-02 ユーシーエル ビジネス ピーエルシー 養子細胞療法に有用なポリペプチド
JP2018504458A (ja) * 2015-01-26 2018-02-15 セレクティスCellectis 操作された免疫細胞の選別/枯渇のための、mAbが推進するキメラ抗原受容体系
JP2018504145A (ja) * 2015-01-26 2018-02-15 セレクティスCellectis 再発性/難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、cd123に結合するキメラ抗原受容体を賦与された、操作されたt細胞受容体ノックアウト免疫細胞
JP2018512153A (ja) * 2015-04-13 2018-05-17 ファイザー・インク B細胞成熟抗原を標的にするキメラ抗原受容体
JP2020512019A (ja) * 2017-03-31 2020-04-23 セレクティス ソシエテ アノニム ユニバーサル抗cd22キメラ抗原受容体操作免疫細胞

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRIAN PHILIP ET AL., BLOOD, vol. 124, no. 8, JPN6025017569, 2014, pages 1277 - 1287, ISSN: 0005772323 *
FEDERICO PEROSA ET AL., JOURNAL OF IMMUNOLOGY, vol. 179, JPN6026001105, 2007, pages 7967 - 7974, ISSN: 0005772325 *
MENG LI ET AL., CELLULAR IMMUNOLOGY, vol. 239, JPN6026001104, 2006, pages 136 - 143, ISSN: 0005772324 *

Also Published As

Publication number Publication date
GB2611448B (en) 2025-01-08
CA3179441A1 (en) 2021-12-02
GB202007842D0 (en) 2020-07-08
GB2611448A (en) 2023-04-05
TW202210503A (zh) 2022-03-16
EP4157318A1 (en) 2023-04-05
AU2021279184A1 (en) 2022-12-22
GB202218768D0 (en) 2023-01-25
WO2021239812A1 (en) 2021-12-02
US20230183311A1 (en) 2023-06-15
CN115955977A (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
US20230183311A1 (en) Polypeptide useful in adoptive cell therapy
JP7824235B2 (ja) キメラ抗原受容体のための新規コンストラクト
JP7519906B2 (ja) ホスホリパーゼa2受容体キメラ自己受容体t細胞の組成物および方法
CN110582509A (zh) 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
AU2016250200B2 (en) Chimeric protein
EP3331913A1 (en) Treatment of cancer using chimeric cd3 receptor proteins
CN113604491A (zh) 嵌合自身抗体受体t细胞的组合物和方法
KR20180041087A (ko) 암을 치료하기 위한 방법 및 조성물
AU2013246648A1 (en) Polypeptide useful in adoptive cell therapy
US20250144137A1 (en) Nucleic acid constructs for expressing polypeptides in cells
JP7404331B2 (ja) 膜結合型IL-10をコードする核酸分子及びそれを発現する遺伝子的にリプログラミングされたTreg
US20250345429A1 (en) Compositions and methods comprising chimeric adaptor polypeptides
JP2022533092A (ja) アセチルコリン受容体キメラ自己抗体受容体細胞の組成物および方法
CN119053618A (zh) 嵌合ilt受体组合物和方法
US20240207405A1 (en) Il2 tethered to its receptor il2rbeta and pore-forming proteins as a platform to enhance immune cell activity
WO2024042318A1 (en) Chimeric antigen receptor (car) to a tcr beta-chain variable region
HK40063360A (en) Compositions and methods of chimeric autoantibody receptor t cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250508

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260702